Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study

The purpose of this study is to evaluate the safety and efficacy of apixaban for the prevention of thromboembolism in adult patients with congenital heart disease (CHD) and non-valvular atrial

apixaban
thromboembolism
arrhythmia
  • 2 views
  • 03 Feb, 2021
  • 8 locations
Monitoring of NOAC Therapy: Standardizing Reference Intervals

This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and rivaroxaban) in ethnic Chinese patients.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients

Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.

  • 39 views
  • 22 Feb, 2021
  • 2 locations
New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study

persons. This study try to better define wether the pharmacology of each of these 3 drugs (dabigatran, rivaroxaban and apixaban) is actually significantly different in very older patients (over 80) and to

anticoagulants
apixaban
fibrillation
rivaroxaban
dabigatran
  • 6 views
  • 23 Jan, 2021
  • 4 locations
Oral Anti-coagulants in Fragile Patients With Percutaneous Endoscopic Gastrostomy and Atrial Fibrillation (ORIGAMI) Pilot Study

bioavailability for apixaban, rivaroxaban, and edoxaban". However, at the moment, there are no evidences supporting unequivocally the use of DOAC via PEG. The purpose of this study is to evaluate the

anticoagulation therapy
apixaban
vitamin k
anticoagulants
vitamin k antagonist
  • 6 views
  • 26 Jan, 2021
  • 1 location
DOAC in Unusual Site Venous Thrombosis

-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators

apixaban
venous thromboembolism
anticoagulants
clot
thrombin
  • 0 views
  • 25 Jan, 2021
  • 1 location
Registry of Patient With Antithrombotic Agents Admitted to an Emergency Department

(Apixaban rivaroxaban, dabigatran ...) should profoundly change the management of venous thromboembolism and cardioembolic event. Because of their risk-benefit, simplicity and convenience of their

  • 0 views
  • 21 Jan, 2021
'Understanding the Electrophysiological Substrate Underlying Persistent Atrial Fibrillation Study II (USURP AF- Study II)'

Atrial fibrillation (AF) is the most common type of chronic heart rhythm disease worldwide, with significant associated co-morbidities. Although there have been advances in understanding the mechanisms of AF, the underlying cause of AF and factors which perpetuate it remain incompletely understood. This is particularly the case for persistent AF …

ablations
persistent atrial fibrillation
arrhythmia
catheter ablation
pulmonary vein isolation
  • 1 views
  • 23 Jan, 2021
  • 1 location